2023 Women’s Cardiometabolic Health and Wellness Masterclass
TARGET AUDIENCE
The educational design of this activity addresses the needs of US-based healthcare professionals, including endocrinologists, cardiologists, internists, primary care clinicians, obstetricians, pharmacists, physicians, nurse practitioners, and physician assistants.
EDUCATIONAL OBJECTIVES
After completing this activity, the participant should be better able to:
- Recognize the symptoms and clinical presentation of acute and chronic cardiovascular diseases in women, including heart failure, valvular disease, and acute coronary syndromes.
- Discuss the relationship between conventional and women-specific cardiometabolic risk factors, as well as their impact on the development of cardiometabolic diseases in women across the lifespan, including diabetes, dyslipidemia, hypertension, obesity, kidney disease, and cardiovascular disease.
- Describe the risk of cardiometabolic disease in women due to adverse pregnancy outcomes across the women’s lifespan.
- Summarize recent evidence for emerging therapies in cardio-renal-metabolic medicine in order to stay current with the most recent updates, including women-specific considerations.
- Select individualized and evidence-based approaches for the management of women with cardio-renal-metabolic risk, including the optimization of CVD prevention, obesity, hypertension, dyslipidemia, kidney disease, and type 2 diabetes.
JOINT PROVIDERSHIP STATEMENT
In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and Cardiometabolic Health Congress (CMHC). PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CONTINUING EDUCATION
PACE designates this enduring activity for a maximum of 12Â AMA PRA Category 1 Creditsâ„¢. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
NURSING CONTINUING EDUCATION
The maximum number of hours awarded for this Continuing Nursing Education activity is 12 contact hours.
Pharmacotherapy contact hours for Advance Practice Registered Nurses will be designated on your certificate.
PHARMACY CONTINUING EDUCATION
PACE designates this continuing education activity for 12 contact hour(s) (1.2 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number – JA4008073-9999-23-229-H01-P Type of activity: Knowledge
DISCLOSURES
Information on planner and faculty disclosures will be provided in the activity.
DISCLOSURE OF CONFLICT OF INTEREST
PACE requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial relationships they may have with ineligible companies. All relevant financial relationships are thoroughly vetted and mitigated according to PACE policy. PACE is committed to providing learners with high-quality accredited CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
METHOD OF PARTICIPATION & REQUEST FOR CREDITÂ
There is a registration fee for this activity (if you were a live attendee please refer to the below note). Registration can be found here. Once registration is complete, you will receive a confirmation email with an access code and link back to this course.
If you attended the 2023 Women’s Health Masterclass, please reach out to info@cardiometabolichealth.org and we will provide you with complimentary access code to this activity.
During the period September 14, 2023 through September 14, 2024, participants must read the learning objectives and faculty disclosures, study the educational activity, and complete the evaluation.  Upon completing, your certificate will be available for print. For questions about receiving certificates, please contact us a CMHC_Eval@cardiometabolichealth.org.
For additional information about the accreditation of this activity, please visit https://partnersed.com
For Pharmacists: Please complete the evaluation instructions above. Upon registering and completing the activity evaluation, your transcript information will be sent to the NABP CPE Monitor Service within 4-6 weeks.
